Seattle Genetics (SGEN)

55.35 +1.57 (2.92%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (4/25/18 *Est.)
- M&A (3/31/18 *Est)

Latest Headlines

Seattle Genetics (SGEN) Announces Expiration of HSR Waiting Period for Acquisition of Cascadian (CASC) February 16, 2018 8:12 AM - StreetInsider Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period February 16, 2018 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Feb 13 Filed by: WELCH DANIEL G February 15, 2018 9:22 PM - SEC Filing Form 10-K SEATTLE GENETICS INC For: Dec 31 February 15, 2018 6:14 AM - SEC Filing Form SC 13G SEATTLE GENETICS INC Filed by: PRICE T ROWE ASSOCIATES INC /MD/ February 14, 2018 2:11 PM - SEC Filing Form SC 13G SEATTLE GENETICS INC Filed by: Capital International Investors February 14, 2018 6:53 AM - SEC Filing JPMorgan Upgrades Seattle Genetics (SGEN) to Overweight February 14, 2018 3:46 AM - StreetInsider Form 4 SEATTLE GENETICS INC For: Feb 09 Filed by: SIEGALL CLAY B February 13, 2018 8:20 PM - SEC Filing Form SC 13G/A SEATTLE GENETICS INC Filed by: FMR LLC February 13, 2018 10:05 AM - SEC Filing Form SC 13G/A SEATTLE GENETICS INC Filed by: VANGUARD GROUP INC February 9, 2018 2:50 PM - SEC Filing Pre-Open Movers 02/09: (PIRS) (FEYE) (NVDA) Higher; (TNDM) (EXPE) (WWD) Lower (more...) February 9, 2018 9:30 AM - StreetInsider Seattle Genetics (SGEN), Pieris Pharmaceuticals (PIRS) Announce Multi-Program Immuno-Oncology Pact February 9, 2018 6:45 AM - StreetInsider Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration February 9, 2018 6:45 AM - MarketWire Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration February 9, 2018 6:45 AM - BizWire Seattle Genetics (SGEN) Commences Tender Offer for Cascadian Therapeutics (CASC) February 8, 2018 5:43 PM - StreetInsider Seattle Genetics Commences Tender Offer for Cascadian Therapeutics, Inc. February 8, 2018 5:39 PM - BizWire Form 4 SEATTLE GENETICS INC For: Feb 05 Filed by: Cline Darren S February 7, 2018 8:18 PM - SEC Filing Seattle Genetics (SGEN) PT Raised to $77 at H.C. Wainwright February 7, 2018 7:24 AM - StreetInsider Seattle Genetics (SGEN) PT Raised to $60 at SunTrust Robinson Humphrey February 7, 2018 7:10 AM - StreetInsider Form 8-K SEATTLE GENETICS INC For: Feb 06 February 6, 2018 4:22 PM - SEC Filing Seattle Genetics (SGEN) Tops Q4 EPS by 2c, Beats on Revenues February 6, 2018 4:05 PM - StreetInsider Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results February 6, 2018 4:02 PM - BizWire Form SC 13D/A SEATTLE GENETICS INC Filed by: BAKER BROS. ADVISORS LP February 5, 2018 4:09 PM - SEC Filing Form 4 BAKER FELIX For: Feb 01 Filed by: SEATTLE GENETICS INC /WA February 5, 2018 4:01 PM - SEC Filing Seattle Genetics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares February 2, 2018 8:30 AM - BizWire Form 8-K SEATTLE GENETICS INC For: Jan 31 February 1, 2018 5:05 PM - SEC Filing Form 424B5 SEATTLE GENETICS INC February 1, 2018 5:03 PM - SEC Filing Form SC 13G SEATTLE GENETICS INC Filed by: BlackRock Inc. February 1, 2018 9:36 AM - SEC Filing Seattle Genetics (SGEN) Prices 11.54M Share Common Offering at $52/Sh February 1, 2018 6:43 AM - StreetInsider Seattle Genetics Announces Pricing of Public Offering of Common Stock February 1, 2018 6:30 AM - BizWire Form FWP SEATTLE GENETICS INC Filed by: SEATTLE GENETICS INC /WA February 1, 2018 6:15 AM - SEC Filing Puma Biotechnology (PBYI) Nerlynx Has More Competition as Seattle Genetics Acquires Tucatinib - Stifel January 31, 2018 12:13 PM - StreetInsider Pre-Open Movers 01/31: (CASC) (SFLY) (KNX) Higher; (BLCM) (MGI) (CACC) Lower (more...) January 31, 2018 9:24 AM - StreetInsider Form 424B5 SEATTLE GENETICS INC January 31, 2018 7:22 AM - SEC Filing Form S-3ASR SEATTLE GENETICS INC January 31, 2018 7:03 AM - SEC Filing Form 8-K SEATTLE GENETICS INC For: Jan 31 January 31, 2018 6:52 AM - SEC Filing Form 8-K SEATTLE GENETICS INC For: Jan 30 January 31, 2018 6:47 AM - SEC Filing Seattle Genetics (SGEN) Announces $550M Common Share Offering January 31, 2018 6:41 AM - StreetInsider Seattle Genetics Announces Proposed Public Offering of Common Stock January 31, 2018 6:40 AM - BizWire Seattle Genetics (SGEN) to Acquire Cascadian Therapeutics (CASC) for $10/Share January 31, 2018 6:31 AM - StreetInsider Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline January 31, 2018 6:30 AM - BizWire Form SC 13G/A SEATTLE GENETICS INC Filed by: BAILLIE GIFFORD & CO January 24, 2018 10:35 AM - SEC Filing Seattle Genetics (SGEN) Announces ADCETRIS Receives EC Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy January 22, 2018 8:13 AM - StreetInsider Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval for CD30-Positive Cutaneous T-Cell Lymphoma after at Least One Prior Systemic Therapy January 22, 2018 8:00 AM - BizWire Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018 January 18, 2018 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Jan 11 Filed by: SIEGALL CLAY B January 16, 2018 8:09 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Jan 11 Filed by: DRACHMAN JONATHAN G January 16, 2018 8:05 PM - SEC Filing Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 8:00 AM - BizWire Seattle Genetics (SGEN) Adcetris Price Raised 3.9% - SunTrust Robinson Humphrey January 2, 2018 1:19 PM - StreetInsider Seattle Genetics (SGEN) Grantred FDA Supplemental Biologics License Application and Grants Priority Review for ADCETRIS (Brentuximab Vedotin) January 2, 2018 8:01 AM - StreetInsider FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma January 2, 2018 8:00 AM - BizWire Seattle Genetics to Present at the J.P. Morgan Healthcare Conference December 19, 2017 8:00 AM - BizWire Banks drag European shares down as investors await Draghi December 14, 2017 3:43 AM - StreetInsider Form 4 SEATTLE GENETICS INC For: Dec 11 Filed by: SIEGALL CLAY B December 13, 2017 8:50 PM - SEC Filing Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY) Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS and Opdivo in R/R Hodgkin Lymphoma December 11, 2017 10:31 AM - StreetInsider Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed or Refracto December 11, 2017 10:30 AM - BizWire Seattle Genetics (SGEN) Reports Five-Year Survival Results from Phase 1 Trial of ADCETRIS (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma December 11, 2017 5:50 AM - StreetInsider Seattle Genetics (SGEN) and Takeda Highlight Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma December 11, 2017 5:45 AM - StreetInsider Seattle Genetics (SGEN) Presents Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma December 11, 2017 5:39 AM - StreetInsider Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma December 10, 2017 6:33 PM - BizWire Seattle Genetics Highlights Five-Year Survival Results from Phase 1 Trial of ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-Cell Lymphoma at ASH Annual Meeting December 10, 2017 9:00 AM - BizWire Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma December 10, 2017 8:00 AM - BizWire Seattle Genetics Highlights Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma at ASH Annual Meeting December 9, 2017 9:00 AM - BizWire Seattle Genetics (SGEN) Announces Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) December 7, 2017 8:01 AM - StreetInsider Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium December 7, 2017 8:00 AM - BizWire Form 4 SEATTLE GENETICS INC For: Dec 04 Filed by: LIU JEAN I December 6, 2017 8:08 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Dec 04 Filed by: DOBMEIER ERIC December 6, 2017 8:05 PM - SEC Filing Form 4 SEATTLE GENETICS INC For: Nov 30 Filed by: HIMES VAUGHN B December 4, 2017 7:54 PM - SEC Filing Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual Meeting December 4, 2017 8:00 AM - BizWire Form 8-K SEATTLE GENETICS INC For: Nov 29 December 1, 2017 12:26 PM - SEC Filing Full Article List